[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @gvanhp Gerard van Hamel Platerink Gerard van Hamel Platerink posts on X about $hrow, $arqt, $knsa, $mdgl the most. They currently have XXX followers and X posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1265441504/interactions)  - X Week XXXXX +1,143% - X Month XXXXX -XX% - X Months XXXXXX +63% - X Year XXXXXX +69% ### Mentions: X [#](/creator/twitter::1265441504/posts_active)  - X Week X +17% - X Month XX +7.70% - X Months XX +329% - X Year XX +414% ### Followers: XXX [#](/creator/twitter::1265441504/followers)  - X Week XXX +2.70% - X Month XXX +18% - X Months XXX +78% - X Year XXX -XX% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1265441504/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) XXXXX% **Social topic influence** [$hrow](/topic/$hrow) #6, [$arqt](/topic/$arqt) 28.57%, [$knsa](/topic/$knsa) 28.57%, [$mdgl](/topic/$mdgl) 28.57%, [$tars](/topic/$tars) 28.57%, [$tvtx](/topic/$tvtx) 28.57%, [$xers](/topic/$xers) 28.57%, [debt](/topic/debt) 14.29%, [cash flow](/topic/cash-flow) 14.29%, [$175m](/topic/$175m) XXXXX% **Top accounts mentioned or mentioned by** [@mufson](/creator/undefined) [@nightowlbiotech](/creator/undefined) [@unicornbiotech](/creator/undefined) **Top assets mentioned** [Arcutis Biotherapeutics, Inc. Common Stock (ARQT)](/topic/$arqt) [Kiniksa Pharmaceuticals, Ltd. Class A Common Stock (KNSA)](/topic/$knsa) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Tarsus Pharmaceuticals, Inc. Common Stock (TARS)](/topic/$tars) [Travere Therapeutics, Inc. Common Stock (TVTX)](/topic/$tvtx) ### Top Social Posts Top posts by engagements in the last XX hours "Restarted a position in $HROW. Fundamentals are solid with positive EBITDA and Free Cashflow. Net debt not trivial at $175M but manageable given FCF+. Revenue growth rate XX% consensus forecast for the next 3-4 years. Trades at 4.2x 2026 rev and 17x 2026 EBITDA. Technicals look good with double cup and handle. Goal is a 2x in XX months. Vamos" [X Link](https://x.com/gvanhp/status/1996332837784752279) 2025-12-03T21:36Z XXX followers, XXX engagements "The fund now comprises $ARQT $HROW $KNSA $MDGL $SNDX $TARS $TVTX $URGN $XERS" [X Link](https://x.com/gvanhp/status/1996332839235949024) 2025-12-03T21:36Z XXX followers, XXX engagements "Sold $DCTH this morning. Effective therapy unmet need etc. but too much friction to adopt and scale = downward guidance revisions. Cheap stock at 2.2x '26 revs w. XX% growth so will keep on watchlist. Now own $ARQT $KNSA $MDGL $TARS $TVTX $XERS" [X Link](https://x.com/gvanhp/status/1985760429550027093) 2025-11-04T17:25Z XXX followers, 3608 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@gvanhp Gerard van Hamel PlaterinkGerard van Hamel Platerink posts on X about $hrow, $arqt, $knsa, $mdgl the most. They currently have XXX followers and X posts still getting attention that total XXX engagements in the last XX hours.
Social category influence finance XXXXX%
Social topic influence $hrow #6, $arqt 28.57%, $knsa 28.57%, $mdgl 28.57%, $tars 28.57%, $tvtx 28.57%, $xers 28.57%, debt 14.29%, cash flow 14.29%, $175m XXXXX%
Top accounts mentioned or mentioned by @mufson @nightowlbiotech @unicornbiotech
Top assets mentioned Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Kiniksa Pharmaceuticals, Ltd. Class A Common Stock (KNSA) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Tarsus Pharmaceuticals, Inc. Common Stock (TARS) Travere Therapeutics, Inc. Common Stock (TVTX)
Top posts by engagements in the last XX hours
"Restarted a position in $HROW. Fundamentals are solid with positive EBITDA and Free Cashflow. Net debt not trivial at $175M but manageable given FCF+. Revenue growth rate XX% consensus forecast for the next 3-4 years. Trades at 4.2x 2026 rev and 17x 2026 EBITDA. Technicals look good with double cup and handle. Goal is a 2x in XX months. Vamos"
X Link 2025-12-03T21:36Z XXX followers, XXX engagements
"The fund now comprises $ARQT $HROW $KNSA $MDGL $SNDX $TARS $TVTX $URGN $XERS"
X Link 2025-12-03T21:36Z XXX followers, XXX engagements
"Sold $DCTH this morning. Effective therapy unmet need etc. but too much friction to adopt and scale = downward guidance revisions. Cheap stock at 2.2x '26 revs w. XX% growth so will keep on watchlist. Now own $ARQT $KNSA $MDGL $TARS $TVTX $XERS"
X Link 2025-11-04T17:25Z XXX followers, 3608 engagements
/creator/twitter::gvanhp